Table 1.
E1 Enzyme Inhibitors | Effects on cancer cells | Ref. |
---|---|---|
Panepophenanthrin | Inhibit the binding of ubiquitin to E1, but has no inhibitory effect on cell growth. [further studies are needed] | [10] |
Himeic acid A | Inhibitory effect on E1 catalytic activity | [12] |
Largazole | Induce G1 phase arrest, which is associated with increased expression of p21 and the recruitment of HDAC1 to E2F1 that results in the proteasomal degradation of E2F1 | [13] |
Hyrtioreticulins A and B | Potent inhibitory ability against the formation of an E1-ubiquitin intermediate | [14] |
PYR-41 | Irreversible inhibitor of E1, inhibit the activation of NF-ҡB, and preventing the proteasome-mediated degradation of IκBα as well as p53 | [17] |
JS-K | Reduction of total ubiquitylated proteins, increased levels of p53 expression | [19] |
NSC624206 | Preventing the ubiquitin-thioester formation step, but has no effect on ubiquitin adenylation in the E1 activation reaction | [18] |
MLN4924 | Attenuates the function of the various CRLs | [20] |
5′-O-sulfamoyl-N(6)-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compound I) | Nonselective UAE-inhibitory activity, forming a covalent adduct Ub-I, thereby inhibiting UAE-dependent ATP-PPi exchange activity and E1-E2 transthiolation | [27] |
MLN7243 | UBA1-selective inhibitor | [28–30] |
ABPA3 | Dual inhibitor of the Ub and NEDD8 E1s | [31] |
Deoxyvasicinone-based compounds: - Dipeptide-conjugated deoxyvasicinone derivative - Valine-linked deoxyvasicinone derivative - N-isopropyl-linked deoxyvasicinone derivative |
NAE-inhibitory effects through disrupting the ATP-binding domain [Biological effects and human cancers remain unknown]. | [32,33] |
Piperacillin 1 | A reversible ATP-competitive inhibitor of NAE; increasing levels of the CRL substrate p27kip1 | [34] |
M22 (1-benzyl-N-(2,4-dichlorophenethyl) piperidin-4-amine) | Inhibitory activities of NAE against human cancers [further studies are needed] | [35] |
LP0040 (2H-chromen-2-one derivative with phenyl substituents ) | Inhibitory activities of NAE against human cancers [further studies are needed] | [36] |
E2 Enzyme Inhibitors | ||
Peptoid compound (Leucettamol A) | Disrupting the formation of the Ubc13–Uev1A complex, and inactivating of NF-kB and sensitization of tumor cells to chemotherapeutic agents | [40,41] |
Dimeric sterols (Manadosterols A and B) | Antagonizing the Ubc13–Uev1A interaction, and more potent than Leucettamol A | [42] |
NSC697923 | Induce cancer cell apoptosis, cell death, initiating cell death by activating JNK pathway | [43] |
CC0651 | Disrupting the activity of human E2 enzyme Cdc34 | [45] |
Triazines compounds | Rad6B-inhibitory activities on levels of its conjugation to both ubiquitin and the substrate H2A | [47] |